If you are dealing with a stubborn injury that will not heal, chronic gut inflammation, or tendon pain that limits your daily life, BPC-157 is one of the peptides I discuss most frequently with patients. The preclinical evidence for tissue repair is among the most extensive of any therapeutic peptide — hundreds of animal studies across dozens of injury models, all pointing in the same direction. The catch, and I will be honest about this throughout, is that large-scale human clinical trials do not yet exist. For a comparative overview of how BPC-157 fits within the broader healing peptide landscape, see Best Peptides for Healing: A Physician’s Ranked Guide.
Here is what the research actually shows, where the evidence is strong, and where it falls short.
At a Glance
| Property | Detail |
|---|---|
| Type | Synthetic analog of endogenous gastric peptide |
| Amino acid count | 15 |
| Primary mechanism | Angiogenesis promotion, growth factor modulation, NO system regulation |
| Evidence level | Extensive animal studies; no large-scale human RCTs |
| Regulatory status | Not FDA-approved; FDA-flagged compounding safety risk; not EMA/BfArM-authorised; WADA-prohibited |
| Route of administration | SC injection, oral, local injection (see our full oral vs injection comparison) |
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a sequence found in human gastric juice. The parent protein, known as BPC, is a component of the gastric mucosal defense system. BPC-157 is a partial sequence of this protein that appears to retain and possibly concentrate its protective biological activity.

The peptide was first characterized by Professor Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. Since then, Sikiric’s laboratory has published an extraordinary volume of research on BPC-157, spanning dozens of studies across multiple organ systems and injury models.
The amino acid sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
BPC-157 is stable in gastric juice — an unusual property for a peptide of this size — which has implications for both its biological role and its therapeutic potential. This stability is likely related to its high proline content, which confers resistance to enzymatic degradation.
Mechanism of Action
The mechanistic picture of BPC-157 is complex and, frankly, not entirely resolved. Multiple pathways have been implicated, and it is not clear whether BPC-157 has a single primary target or whether it genuinely acts through multiple independent mechanisms.
Primary Pathways
- Angiogenesis and Growth Factor Modulation: The most consistently observed mechanism in preclinical studies is the promotion of angiogenesis. BPC-157 appears to upregulate the expression of VEGF and its receptor VEGFR2 in injured tissues. It also appears to upregulate growth hormone receptor expression in injured tissues — a mechanistically distinct effect from direct growth hormone administration.
- The FAK-Paxillin Pathway: In tendon fibroblast studies, BPC-157 has been shown to activate the focal adhesion kinase (FAK)-paxillin signaling pathway. This pathway is central to cell migration, proliferation, and the formation of new extracellular matrix. Activation of FAK-paxillin in tendon cells promotes the organized deposition of collagen.
- Nitric Oxide System Modulation: BPC-157 interacts with the NO system in ways that appear to be context-dependent. In some models, it promotes NO production; in others, it modulates excessive NO production. This context-dependency has led some researchers to describe BPC-157 as a “NO system modulator” rather than a simple NO promoter or inhibitor.
- Gastrointestinal Protection: Given its origin in gastric juice, BPC-157 has demonstrated significant gastrointestinal protective effects in animal models, including protection against NSAID-induced ulceration, acceleration of ulcer healing, and reduction of inflammation in IBD models. For patients dealing with gut barrier dysfunction, BPC-157 is often combined with KPV peptide therapy as part of a comprehensive gut healing protocol.
- Neuroprotective Effects: Several studies have demonstrated neuroprotective effects including protection against dopaminergic neurotoxicity, reduction of brain damage following traumatic injury, and modulation of serotonergic and dopaminergic neurotransmission.
Research Assessment
What the Evidence Shows
Here is where I need to be direct with you. The BPC-157 research literature has specific characteristics that every informed reader should understand.
The animal model data for BPC-157 is, by any reasonable standard, impressive. Across hundreds of published studies, BPC-157 has demonstrated protective and healing effects in nearly every organ system and injury model tested. The consistency of positive results across different research groups and different injury types is notable.
| Claimed Effect | Evidence Level | Key Studies | Assessment |
|---|---|---|---|
| Gastric ulcer protection | Animal studies | Sikiric 2013 | Strong preclinical signal |
| Inflammatory bowel disease | Animal + early human | Sikiric 2006 | Promising |
| Neuroprotection | Animal studies | Vukojevic 2022 | Preliminary |
| Muscle injury repair | Animal studies | Seiwerth 2018 | Promising |
| Cardiac protection | Animal studies | Sikiric 2022 | Preliminary |
What the Evidence Does Not Show
Virtually all of this data comes from animal models. Predominantly rats. As of this writing, there are no published, peer-reviewed, large-scale randomized controlled human trials of BPC-157 for any indication. There have been early-phase clinical trials initiated by Diagen, a Croatian pharmaceutical company, for inflammatory bowel disease, but the results have not been published as full trial reports.
A secondary concern is that an outsized proportion of the BPC-157 literature comes from a single research group. Professor Sikiric’s laboratory has made enormous contributions, and their work is generally well-designed within the constraints of preclinical research. But in evidence-based medicine, independent replication by multiple groups is an important criterion for confidence.
Clinical Applications
BPC-157 is most commonly promoted for the following areas. In each, the support is preclinical or observational:
Musculoskeletal injuries. Tendon injuries, ligament sprains, muscle tears, joint inflammation, and post-surgical recovery. This is the application with the most direct preclinical support and the most clinical observation. For tissue repair applications, BPC-157 is often compared with TB-500, and the two are often discussed side by side, though their combination has never been tested in humans.
Gastrointestinal conditions. Inflammatory bowel disease, leaky gut, NSAID-induced gastropathy, and gastric ulceration.
Post-traumatic brain injury and concussion recovery. Based on the neuroprotective animal data. The clinical evidence here is purely observational.
General tissue healing and recovery. Some clinicians and patients use BPC-157 as a general recovery agent following surgery, intense training, or injury.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Route | Dose Range | Frequency | Duration | Basis |
|---|---|---|---|---|
| Subcutaneous (near the injury or abdominal) | 250-500 mcg | Once or twice daily | 4-8 weeks | Practice protocol |
| Subcutaneous, more serious injury | 500 mcg (one compilation lists up to 1,000 mcg) | Twice daily | 4-6 weeks | Practice protocol |
| Oral, gut symptoms | 500-1,000 mcg | Once or twice daily, empty stomach | 4-8 weeks | Anecdotal |
Important: Dosing information is presented for educational purposes based on published literature. This is not medical advice. Peptide therapy should only be administered under the supervision of a qualified physician. Self-administration carries significant risks.
Note: These dosing ranges are derived from allometric scaling of effective animal doses and from practitioner and community protocols; the basis labels match the protocol table in the dosage guide. They are not based on human dose-finding clinical trials. BPC-157 is not FDA-approved, the FDA lists it among bulk substances that may present significant safety risks in compounding, and WADA names it as a prohibited non-approved substance. For the full breakdown by route, see the BPC-157 Dosage Guide.
For patients and clinicians weighing BPC-157, a dedicated guide to BPC-157 contraindications covers which populations, including active cancer patients, transplant recipients, and those on anticoagulants, require careful evaluation before use.
What People Report: What Works and What Doesn’t
Sources: the aggregated community data set (Peptide Protocol Wiki, 150 reports), the protocol and warning-sign lists on Peptide DB, and the three small published human series, summarised in a 2026 systematic review (Poolton 2026). These are patterns, not proof. Doses and their sources are in the protocol table of the dosage guide.
Reported to work
- Less pain and better movement after tendon, ligament and muscle injuries, the most common reason people use it. At 250-500 mcg SC once or twice daily, most say they notice a change within 1-2 weeks and see most of the progress by weeks 3-4.
- Gut complaints with oral use: gastritis-type pain, bloating and IBS-type symptoms at 500-1,000 mcg on an empty stomach.
- The clinic case series point the same way. In a retrospective series of knee injections, 11 of 12 patients who had BPC-157 alone reported significant improvement in knee pain (Lee & Padgett 2021), and 10 of 12 women with interstitial cystitis reported complete symptom resolution after one bladder procedure (Lee 2024). Neither study had a control group.
Mixed or unclear
- Injecting next to the injury rather than into belly fat. Many users swear by it, but the idea comes from the community; the animal studies gave BPC-157 systemically.
- Whether the improvement is BPC-157 or time. Users usually start days to weeks after an injury, often alongside physiotherapy or rest, and nothing in a self-report separates the peptide from natural healing.
- Higher doses (500 mcg twice daily). Some describe a faster onset; nobody has compared it with standard dosing.
- Oral dosing for problems outside the gut.
Reported not to work, or disappointing
- A share of users notice nothing. Community data skew positive because people with dramatic results post more often than people without them.
- Side effects people describe are mostly mild: redness at the injection site. Headache and dizziness appear in the warning-sign lists, and the published series reported no treatment-related adverse events in 30 people.
- Product quality varies widely between sellers, which makes negative and positive reports equally hard to interpret.
What a properly designed trial would need to show: in a defined injury such as chronic patellar or Achilles tendinopathy, a randomised, placebo-controlled comparison of a fixed SC dose for 6-8 weeks, with validated pain and function scores, imaging, and follow-up at 6 months.
Safety and Side Effects
Known
In the published preclinical literature, BPC-157 has demonstrated an unusually clean safety profile. No lethal dose has been identified in animal studies. No organ toxicity has been reported. No serious adverse events have been reported in the limited human clinical experience. The most common side effects reported by patients are injection site reactions (mild redness, occasional bruising) and transient warmth or flushing.
Theoretical Concerns
The angiogenesis-promoting properties of BPC-157 raise a theoretical concern in the context of existing malignancies. Tumor growth depends on angiogenesis, and any agent that promotes new blood vessel formation could theoretically support tumor vascularization. This concern has not been borne out in animal studies, but it deserves acknowledgment in oncology patients. For a broader discussion of peptide safety considerations, see our peptide safety overview.
Contraindications
No formal contraindications have been established through clinical trials. Based on mechanism of action and clinical judgment: active malignancy (theoretical concern), pregnancy and lactation (no safety data), and children (no pediatric data). Patients on anticoagulant therapy should exercise caution given the vascular effects.
Drug and Supplement Interactions
No drug interactions have been formally studied in humans. This represents a gap in the evidence, not evidence of safety. Based on mechanistic considerations, theoretical interactions could exist with anticoagulants (given effects on vascular biology) and immunomodulatory agents.
Clinical Perspective
The questions I hear most about BPC-157 concern musculoskeletal injury and gastrointestinal healing. My answer is that the animal data are genuinely interesting, but that interest does not replace the human trials that would tell us whether it works, at what dose, and with what risks. For anyone wondering what an injectable treatment involves and why self-injecting an unapproved peptide is risky, see How to Inject Peptides: A Step-by-Step Patient Guide.
For tendon injuries such as Achilles tendinopathy and lateral epicondylitis, and for joint problems such as knee osteoarthritis, the treatments with human evidence come first: structured loading rehabilitation and, where appropriate, established injection therapies such as platelet-rich plasma (PRP). Combining BPC-157 with other agents has not been studied in humans.
The dramatic, transformative results described in online testimonials are not supported by any controlled human data. BPC-157 is not a miracle compound, and anyone expecting dramatic overnight improvements is likely to be disappointed.
The honest answer is that BPC-157 is a peptide that deserves continued research, but until that research is complete, honest uncertainty is the most responsible position.

Clinical Perspective — Dr. med. univ. Julian Douwes
The situation patients most often ask me about is post-surgical tendon and ligament recovery, such as rotator cuff repairs and Achilles reconstructions, where rehabilitation timelines are frustratingly long. When I coach patients through this decision (mostly in the US), the protocol most commonly used is 250 mcg subcutaneously twice daily, injected as close to the injury site as practical, for six weeks, and BPC-157 is frequently combined with TB-500 at 2-2.5 mg twice weekly, on the rationale that the two peptides act through different angiogenic pathways. I make clear that this is extrapolated from animal data and clinical practice, not from human dose-finding trials, and that BPC-157 carries an FDA safety flag for compounding (see Peptide Stacking for what combining peptides does and does not tell us). What does have evidence for tissue repair is progressive rehabilitation, adequate protein, and, as an adjunct with some trial support, hydrolyzed collagen peptides. I am skeptical of the dramatic overnight recovery stories that circulate online.
This reflects my professional opinion. It is not a substitute for individual medical advice.
References
- Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016;14(8):857-865. PMID 27138887
- Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011;110(3):774-780. PMID 21030672
- Chang CH, et al. “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.” Molecules. 2014;19(11):19066-19077. PMID 25415472
- Krivic A, et al. “Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation.” J Orthop Res. 2006;24(5):982-989. PMID 16583442
- Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.” Inflammopharmacology. 2006;14(5-6):214-221. PMID 17186181
- Seiwerth S, et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.” Curr Pharm Des. 2018;24(18):1972-1989. PMID 29998800
- Vukojevic J, et al. “Pentadecapeptide BPC 157 and the central nervous system.” Neural Regen Res. 2022;17(3):482-487. PMID 34380875
- Sikiric P, et al. “Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157.” Curr Pharm Des. 2013;19(1):76-83. PMID 22950504
- Sikiric P, et al. “Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation.” Biomedicines. 2022;10(11):2696. PMID 36359218
- Hsieh MJ, et al. “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.” J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966
- Gwyer D, et al. “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell Tissue Res. 2019;377(2):153-159. PMID 30915550
Disclaimer: This article is intended for educational purposes. It reflects current published research and one physician’s clinical perspective. It is not medical advice. BPC-157 is not approved by the FDA for any therapeutic indication. Consult a qualified physician before pursuing any peptide therapy.